New registry to monitor migraine drug safety in pregnancy
NCT ID NCT05046613
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 33 times
Summary
This study follows pregnant women with migraine who either took the medication rimegepant or did not, to see how it affects mothers and their babies. Researchers will track birth defects, pregnancy complications, and infant health up to 12 months after birth. The goal is to gather safety information, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Evidera, a PPD business unit
RECRUITINGWilmington, North Carolina, 28401, United States
Conditions
Explore the condition pages connected to this study.